The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2019 | Tailored treatment strategies for CLL
Here, Danielle Brander, MD, of the Duke University School of Medicine, Durham, NC, discusses tailored treatment strategies for chronic lymphocytic leukemia (CLL), including the use of B-cell receptor signalling inhibitors, and the BCL-2 inhibitor venetoclax. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.
